79 RISK OF MYELODYSPLASTIC SYNDROMES IN WELL-DIFFERENTIATED THYROID CANCERS TREATED WITH RADIOACTIVE IODINE

Thyroid cancer refers to various cancers arising from thyroid gland. Differentiated thyroid cancers (DTCs) include papillary, follicular, and Hurthle cell carcinomas and represent cancers retain normal thyroid functions such as iodine uptake. Radioactive iodine (RAI) is generally used for upfront treatment of metastatic DTCs, but RAI refractory DTCs remain to be clinical challenges. Sorafenib and lenvatinib were approved for the treatment of RAI refractory DTCs and more recently, genomics-based targeted therapies have been developed for NTRK and RET gene fusion-positive DTCs. Poorly differentiated and anaplastic thyroid cancers (ATCs) are extremely challenging diseases with aggressive courses. BRAF/MEK inhibition has been proven to be highly effective in BRAF V600E mutation-positive ATCs and immune checkpoint inhibitors have shown promising activities. Medullary thyroid cancers, which arise from parafollicular cells of thyroid, represent a unique subset of thyroid cancer and mainly driven by RET mutation. In addition to vandetanib and cabozantinib, highly specific RET inhibitors such as selpercatinib and pralsetinib have demonstrated impressive activity and are in clinical use.

Download Full-text

Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases

Clinical Ophthalmology ◽

10.2147/opth.s71708 ◽

2014 ◽

pp. 2479 ◽

Cited By ~ 1

Author(s):

Mutahir Tunio ◽

Khalid Hussain AL-Qahtani ◽

Mushabbab Al-Asiri ◽

Naji J. Aljohani ◽

Yasser Bayoumi ◽

...

Keyword(s):

Radioactive Iodine ◽

Nasolacrimal Duct ◽

Nasolacrimal Duct Obstruction ◽

Thyroid Cancers ◽

Duct Obstruction ◽

Iodine 131 ◽

Differentiated Thyroid Cancers ◽

Radioactive Iodine 131

Download Full-text

Molecular Profile of Locally Aggressive Well Differentiated Thyroid Cancers

Scientific Reports ◽

10.1038/s41598-020-64635-8 ◽

2020 ◽

Vol 10 (1) ◽

Author(s):

Leila J. Mady ◽

Michael C. Grimes ◽

Nayel I. Khan ◽

R. Harsha Rao ◽

Simion I. Chiosea ◽

...

Keyword(s):

Molecular Profile ◽

Thyroid Cancers ◽

Well Differentiated ◽

Differentiated Thyroid Cancers

Download Full-text

Clinical utility of immunohistochemistry using the novel anti-BRAF V600E antibody (clone RM8) for detection of the BRAF V600E mutant protein in papillary thyroid cancers

International Journal of Molecular and Immuno Oncology ◽

10.18203/issn.2456-3994.intjmolimmunooncol20180471 ◽

2018 ◽

Vol 3 (1) ◽

pp. 28 ◽

Cited By ~ 2

Author(s):

Arvind Krishnamurthy ◽

Vijayalakshmi Ramshankar ◽

Kanchan Murhekar ◽

Vidyarani Shyamsundar ◽

Pavithra B. Desai ◽

...

Keyword(s):

Gold Standard ◽

Braf V600e ◽

Mutant Protein ◽

Papillary Thyroid ◽

Thyroid Cancers ◽

Thyroid Carcinomas ◽

Well Differentiated ◽

Differentiated Thyroid Cancers ◽

Kappa Agreement ◽

Formalin Fixed

Background: Molecular markers are gaining increasing importance as diagnostic and prognostic tools in patients with well differentiated thyroid cancers and BRAF V600E mutation has received wide attention in this regard Aim: To evaluate the clinical value of immunohistochemistry (IHC) using anti-BRAF V600E antibody (clone RM8) for detection of the BRAF V600E mutant protein in formalin-fixed and paraffin-embedded tissues of patients with papillary thyroid carcinomas. Materials and Methods: Patients who were managed for well differentiated thyroid cancers (n = 79) during the years 2005 and 2006 were included in the study. We evaluated the fidelity of the RM8 antibody specific for the BRAF V600E and compared its detection accuracy to real time polymerase chain reaction (PCR), which was taken as the gold standard. Results: Mutant BRAF V600E antibody was studied in 79 tissue sections, out of which 21 (26.5%) had staining for BRAF V600E in >20% of the tumour cells and these were considered positive. The BRAF staining was moderate in 10 (47.6%), strong in 9 (42.5%) and very strong in 2 (9.5%) of sections stained. There was a statistically significant concordance (P = 0.000) with quantitative PCR (qPCR) for BRAF mutant taken as standard. (Kappa agreement: 0.881) Further, the receiver operating characteristics (ROC) curve showed that IHC can be used as a comparable standard to the qPCR. The highest possible sensitivity of 92% and specificity of 92.6% could be achieved by considering the cytoplasmic positivity of >20% of cells with moderate to strong intensity (AUC = 0.923) Conclusion: Our study has shown that BRAF V600E IHC can be done in a conventional manner using rabbit monoclonal antibody RM8 on formalin-fixed and paraffin-embedded tissues of patients with papillary thyroid carcinomas. With a comparable diagnostic accuracy to the gold standard qPCR testing and with an added advantage of being cost effective, this technology can be considered for use as a first-line method for detection of BRAF V600E mutations, especially in resource constrained settings.

Download Full-text